X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (392) 392
humans (361) 361
oncology (322) 322
chemotherapy (211) 211
single-agent bevacizumab (208) 208
bevacizumab (177) 177
phase-ii trial (172) 172
female (171) 171
cancer (138) 138
middle aged (134) 134
aged (133) 133
glioblastoma (124) 124
single-agent (122) 122
male (117) 117
antineoplastic combined chemotherapy protocols - therapeutic use (113) 113
adult (108) 108
brain neoplasms - drug therapy (107) 107
clinical neurology (99) 99
treatment outcome (97) 97
antineoplastic agents - therapeutic use (92) 92
care and treatment (91) 91
glioblastoma - drug therapy (88) 88
newly-diagnosed glioblastoma (83) 83
recurrent glioblastoma (81) 81
angiogenesis inhibitors - therapeutic use (75) 75
temozolomide (75) 75
survival (74) 74
hematology, oncology and palliative medicine (68) 68
medicine & public health (68) 68
endothelial growth-factor (67) 67
glioblastoma multiforme (65) 65
disease-free survival (64) 64
neoplasm recurrence, local - drug therapy (63) 63
radiotherapy (63) 63
phase-iii trial (61) 61
prognosis (61) 61
plus irinotecan (58) 58
angiogenesis (55) 55
drug therapy (55) 55
lung neoplasms - drug therapy (54) 54
pharmacology & pharmacy (54) 54
carcinoma, non-small-cell lung - drug therapy (53) 53
clinical trials (53) 53
trial (52) 52
malignant glioma (50) 50
aged, 80 and over (49) 49
research (49) 49
brain neoplasms - pathology (48) 48
antimitotic agents (47) 47
antineoplastic agents (47) 47
bevacizumab - therapeutic use (47) 47
randomized phase-iii (46) 46
high-grade gliomas (44) 44
1st-line treatment (43) 43
adjuvant temozolomide (43) 43
antineoplastic combined chemotherapy protocols - adverse effects (42) 42
health aspects (42) 42
retrospective studies (42) 42
bevacizumab plus irinotecan (41) 41
clinical trials as topic (41) 41
gliomas (41) 41
vascular endothelial growth factor (41) 41
glioblastoma - pathology (40) 40
survival rate (40) 40
combination (39) 39
neoplasm staging (39) 39
neurology (39) 39
therapy (39) 39
animals (38) 38
brain neoplasms - mortality (38) 38
radiation-therapy (38) 38
antibodies, monoclonal, humanized - therapeutic use (37) 37
survival analysis (37) 37
brain neoplasms - therapy (36) 36
high-grade glioma (36) 36
quality of life (36) 36
glioma (35) 35
ovarian cancer (35) 35
glioblastoma - mortality (34) 34
tumors (34) 34
analysis (33) 33
antibodies, monoclonal - therapeutic use (33) 33
cancer therapies (33) 33
lung neoplasms - pathology (33) 33
quality-of-life (33) 33
randomized-trial (33) 33
surgery (33) 33
carboplatin (32) 32
carcinoma, non-small-cell lung - pathology (32) 32
metastasis (32) 32
progression-free survival (32) 32
young adult (32) 32
deoxycytidine - analogs & derivatives (31) 31
development and progression (31) 31
disease progression (31) 31
glioma - drug therapy (31) 31
paclitaxel (31) 31
patients (31) 31
recurrent malignant glioma (31) 31
irinotecan (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 05/2015, Volume 121, Issue 9, pp. 1456 - 1462
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 343 - 343
Journal Article
Journal Article
JOURNAL OF NEURO-ONCOLOGY, ISSN 0167-594X, 03/2012, Volume 107, Issue 1, pp. 155 - 164
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Medicine, ISSN 0025-7974, 06/2015, Volume 94, Issue 24, pp. e975 - e975
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 10/2017, Volume 135, Issue 1, pp. 99 - 105
Journal Article
International Journal of Cancer, ISSN 0020-7136, 03/2019, Volume 144, Issue 6, pp. 1331 - 1344
Bevacizumab, a VEGF‐targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma. We investigated this pattern using both a human... 
bevacizumab | brain infiltration | antiangiogenic therapy | glioblastoma | PLXDC1 | PROLONGS SURVIVAL | GLIOMA | PHASE-III | COMBINATION | BLOOD-BRAIN-BARRIER | TEMOZOLOMIDE | SINGLE-AGENT | IN-VITRO | ONCOLOGY | ANTI-VEGF THERAPY | EXPRESSION | Bevacizumab - pharmacology | Bevacizumab - therapeutic use | Endothelial Cells | Coculture Techniques | Humans | Brain Neoplasms - pathology | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Neoplasm Proteins - metabolism | Rats, Nude | Adult | Brain Neoplasms - mortality | Neoplasm Proteins - genetics | Endothelium - pathology | Brain - cytology | Rats | Receptors, Cell Surface - metabolism | Treatment Outcome | Brain Neoplasms - drug therapy | Antineoplastic Agents, Immunological - pharmacology | Endothelium - cytology | Brain - drug effects | Xenograft Model Antitumor Assays | Endothelium - drug effects | Animals | Antineoplastic Agents, Immunological - therapeutic use | Glioblastoma - pathology | Survival Analysis | Brain - pathology | Cell Line, Tumor | Glioblastoma - drug therapy | Glioblastoma - mortality | RNA, Small Interfering - metabolism | Receptors, Cell Surface - genetics | Tropism | Brain | Animal models | Mesenchyme | Tumor cells | Xenotransplantation | Glioblastoma | Tubules | Endothelial cells | Endothelium | Bevacizumab | Metastases | Glioma cells | Xenografts | Monoclonal antibodies | Infiltration | Vascular endothelial growth factor | Niches | Tumors | Index Medicus | Molecular Cancer Biology
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2015, Volume 21, Issue 19, pp. 4248 - 4250
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 1/2010, Volume 96, Issue 2, pp. 259 - 269
Journal Article
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 1/2012, Volume 106, Issue 1, pp. 121 - 125
Journal Article